Table 1

IFTA + inflammation prevalence estimates

StudyPopulationBiopsyTime post-TransplantPrevalenceDefinitionRef
Park et al LD recipients
2000–2007		Protocol1 year20/151
13%		Mayo 41
Cosio et al LD and DD recipients
1998–2001		Protocol1 year53/292
18%		Mayo 10
Gago et al LD and DD recipients
2000–2006		Protocol:
151/207, 73%
Indication: 56/207, 27.1%		16.9±15.5 mos
(1, 3, 5 years)		207/795
26%		Mayo 42
Gago et al LD and DD recipients
2000–2006		Protocol*1 year14.4%Mayo 42
Cosio et al LD and DD recipients
1999–2010
LD=78%		Protocol1 year86/935
9.5%†		Mayo 11
Ho et al LD and DD recipientsProtocol2 years28/111
25%‡		Mayo 56
Ho et al LD and DD recipientsProtocol6 mos22/94
23.4%		Mayo 56
TMAKPLD and DD recipientsProtocol6 mos48/222
21.6%		Mayo
TMAKPLD and DD recipientsProtocol6 moPure IFTA alone (ci+ct ≥2)§
93/222
41.9%
García-Carro et al LD and DD recipientsProtocol6 wks108/598
18.1%		Oslo 43
García-Carro et al LD and DD recipientsProtocol1 year125/588¶
21.25%		Oslo 43

  • The most recent Banff classification has been revised to include i-IFTA as part of chronic active TCMR. Prevalence estimates for IFTA + inflammation were used, as prior to February 2018, there was no internationally accepted definition for IFTA + inflammation. The primary composite outcome for i-IFTA will be measured using the new Banff schema.37

  • *They did not explicitly state that the 1 year 14.4% reported IFTA + inflammation was from protocol biopsies, but based on their treatment protocols, it is assumed to be largely protocol biopsies.

  • †Reported as 9.5%, but calculated as 9.2%.

  • ‡It is anticipated that later protocol biopsies would have higher rates of IFTA + inflammation, based on 1, 3, 5-year biopsy data from Gago et al.42

  • §Only 16 cases met the ‘conservative criteria for IFTA + inflammation’: ci +ct ≥2, i>0 (16/222, 7.2%). The whole table is otherwise scored with the Mayo clinic criteria for IFTA + inflammation.

  • ¶Personal communication: Daniel Serón, Clara García-Carro and Anna Reisaeter.

  • DD, deceased donor; LD, living donor; mo, month; TCMR, T-cell mediated rejection; TMAKP, Transplant Manitoba Adult Kidney Program; wks, weeks.